[Different treatment modalities of patients with stage III lung cancer].
OBJECTIVE
In order to improve the survival-rates and study the long-term therapeutic effect of stage III lung cancer patients with different treatment modalities.


METHODS
From 1995 to 2004, 1921 patients of stage III lung cancer treated at our hospital were retrospectively analyzed to compare the long-term therapeutic effect of different treatment modalities. There were 606 cases in the combined therapy group (mainly surgical with combined treatment of chemotherapy & radiotherapy), 317 cases in the surgery alone group and 998 cases in the non-surgical group. The 1, 3, 5-year survival rates of these three groups were 66.0% (400/606) vs. 62.7% (199/317) vs. 51.2% (511/998), 32.34% (196/606) vs. 21.45% (68/317) vs. 8.15% (81/998), 19.31% (117/606) vs. 13.2% (42/317) vs. 4.2% (42/998) respectively. In comparison, 1, 3, 5-year survival rates of the combined therapy group was higher than the surgery alone and non-surgical groups; Significant differences in 1-year survival rates were found between the combined therapy group and the surgery alone group or the non-surgical group (P < 0.01) and significant differences in 3, 5-year survival rates among these three groups.


CONCLUSIONS
The combined therapy of radical resection with chemotherapy and radiotherapy is the best treatment modality for stage III lung cancer.
Yu
Da-ping
DP
Department of Thoracic Tumor, Beijing Tuberculosis & Thoracic Tumor Hospital, Beliing 101149, China.
Duan
Yong
Y
Wang
Zi-tong
ZT
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011013:Pneumonectomy; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome